ERBB2 and breast cancer: In one study, the sensitivity of a panel of human breast cancer and other epithelial tumour cell lines to gefitinib was found not to be dependent on overexpression of EGFR (Moasser et al, 2001), and was also suggested to be related to erbB2 expression (Anderson et al, 2001).